Hematopoietic Growth Factors: Supportive and Priming Effects in AML
Growth factors have been administered after chemotherapy in 12 studies. Eight studies showed benefits in neutropenia and seven studies benefits in infections or survival or remissions. Clinical benefits are mainly found in high-risk patients. There are five negative studies according to major benefits, all five studies using E. coli produced GM-CSF. Growth factors before or together with chemotherapy were given in nine studies with trends to more remissions in one and to longer disease-free survival in three studies. Extending the priming strategy to more chemotherapy courses than having been done so far may further improve the antileukemic effect.
KeywordsAcute Myeloid Leukemia Acute Myelogenous Leukemia Cytosine Arabinoside Hematopoietic Growth Factor Acute Myeloid Leukemia Patient
Unable to display preview. Download preview PDF.
- 3.Heil G, Hoelzer D, Sanz MA et al. (1995) Results of a randomized double-blind placebo controlled phase III study of filgrastim in remission induction and early consolidation therapy for adults with de-novo acute myeloid leukemia. Blood 86 (suppl 1): 267aGoogle Scholar
- 4.Link H, Wandt H, Schönrock-Nabulsi P et al. (1996) G-CSF (Lenograstim) after chemotherapy for acute myeloid leukemia: A placebo controlled trial. Blood 88 (suppl 1): 666aGoogle Scholar
- 6.Rowe, JM, Andersen J, Mazza JJ et al. (1995) A randomized placebo-controlled phase III study of granulocyte-macrophage colony stimulating factor (GM-CSF) in adult patients (> 55–70 years) with acute myelogenous leukemia (AML). A study of the Eastern Cooperative Oncology Group (E1490). Blood 86: 457–462PubMedGoogle Scholar
- 7.Ohno R, Miyawaki S, Hatake K et al. (1995) Macrophage colony stimulating factor (M-CSF) reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia (AML): A double-blind controlled study. Blood 86 (suppl 1): 266aGoogle Scholar
- 9.Witz F, Harousseau JL, Sadoun D et al. (1997) GM-CSF during and after remission induction treatment for elderly patients with acute myeloid leukemia (AML). Hematol Blood Transfus 40: 852–856Google Scholar
- 11.Löwenberg B, Suciu S, Zittoun R et al. (1995) GM-CSF during as well as after induction chemotherapy (CT) in elderly patients with acute myeloid leukemia (AML). The EORTC/HOVON phase III trial (AML 11). Blood 86 (suppl 1): 433aGoogle Scholar
- 12.Zittoun R, Suciu S, Mandelli F et al. (1996) Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: A randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 14: 2150–2159PubMedGoogle Scholar
- 15.Zühlsdorf M, Busemann C, Weißpfennig S et al. (1994) Priming with rhGM-CSF or rh-IL-3 for AML progenitors versus CFU-GM in vivo and in vitro: Significant increase in therapeutic ratio for cytosine arabinoside. Proc AACR 85: 211Google Scholar
- 19.Estey E, Hall PT, Kantarjian H et al. (1992) Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose Ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood 79: 2246–2255PubMedGoogle Scholar
- 21.Büchner Th, Hiddemann W, Wörmann B et al. (1996) Age and karyotype-dependent effect of GM-CSF multiple course priming in AML. Blood 88 (suppl 1): 214aGoogle Scholar
- 22.Baer M.R., Bernstein SH, Brunetto VL et al. (1993) In vivo recombinant human G-CSF priming in previously untreated acute myeloid leukemia. Blood 26 Suppl 1: 328aGoogle Scholar
- 23.Estey E, Thall P, Andreeff M et al. (1994) Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: Comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 12: 671–678PubMedGoogle Scholar